A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only

Journal of Clinical Microbiology

Volumn 51, Issue 6, 2013, Pages 1757-1761

  Aitken, Susan C ^a   Bronze, Michelle ^b   Wallis, Carole L ^c   Stuyver, Lieven ^d   Steegen, Kim ^b,e   Balinda, Sheila ^f   Kityo, Cissy ^f   Stevens, Wendy ^b,e   Rinke De Wit, Tobias F ^g,h   Schuurman, Rob ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c LANCET LABORATORIES   (South Africa)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^f JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^g AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^h PharmAccess International   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

AFRICA; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRIED BLOOD SPOT TESTING; EUROPE; GENE SEQUENCE; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UGANDA; VIRUS DETECTION; VIRUS LOAD; VIRUS RECOMBINANT;

AFRICA; CHILD; DEVELOPING COUNTRIES; DNA PRIMERS; DRUG RESISTANCE, VIRAL; EUROPE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878516155     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00118-13     Document Type: Article

References (19)

1. WHO/UNAIDS/UNICEF. 2010. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. http://whqlibdoc.who.int/publications/2010/9789241500395-eng.pdf.
2. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KCE, Nankya I, Schuurman R, Wit FW, Stevens W, van Vugt M, Rinke de Wit TF. 2011. HIV-1 drug resistance among antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: multicentre observational study. Lancet Infect. Dis. 11:750 -759.
3. WHO. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf.
4. Aitken SC, Tempelman H, Schrooders P, van Bussel E, Slabbert M, Schuurman R, Wensing AM. 2011. Limited PI resistance after failure of second-line therapy in rural South African setting. Antivir. Ther. 16:A143. http://www.aegis.org/ DisaplayConf/abstList.aspx?Conf=75.
5. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. 2011. Protease inhibitor resistance is uncommon in HIV-1 subtypeCinfected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res. Treat. 2011:769627. doi:10.1155/2011/769627.
6. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. 2010. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect. Dis. 10:155-166.
7. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. 2010. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J. Acquir. Immune Defic. Syndr. 53:480-484.
8. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J. 2009. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23:1127-1134.
9. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2010. Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18:156-163.
10. Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, Wallis CL, Stevens W, Rinke de Wit TF, Stuyver LJ. 2010. A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences. AIDS Res. Ther. 7:38. doi:10.1186/1742-6405-7- 38.
11. Aitken SC, Kliphuis A, Wallis CL, Chu ML, Fillekes Q, Barth R, Stevens W, Rinke de Wit TF, Schuurman R. 2012. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J. Clin. Virol. 54:21-25.
12. Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, Vugt MV, Rinke de Wit TF. 2012. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int. J. Epidemiol. 41:43-54.
13. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. (Oxf.) 41:95-98.
14. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, Mandaliya K, Plum J, Verhofstede C. 2006. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J. Virol. Methods 133:137-145.
15. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TF, Stevens W. 2010. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J. Virol. Methods 163:505-508.
16. Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D. 2008. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J. Antimicrob. Chemother. 62:1191-1198.
17. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, Heneine W, de Mendoza C, Garcia-Lerma JG. 2007. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21:2503-2511. (Pubitemid 350145182)
18. Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C. 2007. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J. Clin. Microbiol. 45:3342-3351. (Pubitemid 47585660)
19. WHO. 2010. Manual for HIV drug resistance testing using dried blood spot specimens. http://www.who.int/hiv/topics/drugresistance/dbs-protocol.pdf.